Aldeyra Therapeutics, INC 10-K annual reports

Aldeyra Therapeutics' 2025 annual report details reduced net losses, ongoing reproxalap regulatory delays, and strategic pipeline advancements.

Aldeyra Therapeutics files an amendment to its original Form 10-K to correct an administrative error in the consent of its independent registered public accounting firm.

Aldeyra Therapeutics navigates a critical period with its lead drug reproxalap awaiting FDA decision, while managing ongoing financial needs and strategic collaborations.

Aldeyra Therapeutics extends its lease agreement and files its annual report on Form 10-K, detailing financial results and business activities.